nafamostat has been researched along with Spinal Cord Injuries in 2 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Spinal Cord Injuries: Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nafamostat mesilate treatment significantly improved locomotion recovery as assessed by hindlimb BBB scores and the inclined plane test." | 5.48 | Nafamostat mesilate attenuates inflammation and apoptosis and promotes locomotor recovery after spinal cord injury. ( Duan, HQ; Fan, BY; Feng, SQ; Kong, XH; Li, B; Shi, HY; Sun, C; Wu, QL; Yao, X; Zhang, Y; Zhao, CX; Zhou, XF, 2018) |
| "As nafamostat is a serine protease inhibitor known to target thrombin, we used argatroban (Arg), a thrombin-specific inhibitor, as a positive control in the time window experiments." | 1.72 | Delayed administration of nafamostat mesylate inhibits thrombin-mediated blood-spinal cord barrier breakdown during acute spinal cord injury in rats. ( Fan, B; Feng, S; Kong, X; Li, M; Li, W; Liu, X; Ma, L; Pang, Y; Shen, W; Sun, C; Yao, X; Zhang, J; Zhao, C; Zhao, X; Zhou, T, 2022) |
| "Nafamostat mesilate treatment significantly improved locomotion recovery as assessed by hindlimb BBB scores and the inclined plane test." | 1.48 | Nafamostat mesilate attenuates inflammation and apoptosis and promotes locomotor recovery after spinal cord injury. ( Duan, HQ; Fan, BY; Feng, SQ; Kong, XH; Li, B; Shi, HY; Sun, C; Wu, QL; Yao, X; Zhang, Y; Zhao, CX; Zhou, XF, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, C | 1 |
| Zhou, T | 1 |
| Zhao, X | 1 |
| Pang, Y | 1 |
| Li, W | 1 |
| Fan, B | 1 |
| Li, M | 1 |
| Liu, X | 1 |
| Ma, L | 1 |
| Zhang, J | 1 |
| Sun, C | 2 |
| Shen, W | 1 |
| Kong, X | 1 |
| Yao, X | 2 |
| Feng, S | 1 |
| Duan, HQ | 1 |
| Wu, QL | 1 |
| Fan, BY | 1 |
| Shi, HY | 1 |
| Zhao, CX | 1 |
| Zhang, Y | 1 |
| Li, B | 1 |
| Kong, XH | 1 |
| Zhou, XF | 1 |
| Feng, SQ | 1 |
2 other studies available for nafamostat and Spinal Cord Injuries
| Article | Year |
|---|---|
Delayed administration of nafamostat mesylate inhibits thrombin-mediated blood-spinal cord barrier breakdown during acute spinal cord injury in rats.
Topics: Animals; Benzamidines; Blood-Brain Barrier; Endothelial Cells; Evans Blue; Guanidines; Matrix Metall | 2022 |
Nafamostat mesilate attenuates inflammation and apoptosis and promotes locomotor recovery after spinal cord injury.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Benzamidines; Disease Models, Animal; F | 2018 |